Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07287332 · ClinicalTrials.gov registry record · NA

BLOOM: Pragmatic Feasibility Trial

A NA study of Sepsis and Infection, sponsored by Mayo Clinic.

Recruiting
Registry status
NA
Development phase
300
Enrollment target
1
Study location

NCT07287332 is a NA study of Sepsis and Infection that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 300 participants, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07287332, a NA study of Sepsis and Infection, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
NA
Development phase
300 participants
Enrollment target
1
Study location

Study Summary

The goal of this study is to compare two different ways of dosing cefepime, an antibiotic for very sick patients - the usual approach to dosing or a new dosing method. The new dosing method uses only doses that are available in normal care, but choosing between the different doses is based on more information about the patient's body including their kidney function. The primary purpose of this study is to test how easy it is for healthcare professionals to use the new dosing method and how best to conduct the trial. The study will also assess if the new dosing method helps patients recover faster and reduces side effects.

Conditions Studied

Interventions

  • OTHER Usual Care
  • OTHER Up-front individualized dosing algorithm

Study Locations (1)

Minnesota

  • Mayo Clinic in Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2026-01-15
Est. Completion 2027-07
Phase NA

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT07287332

The ClinicalTrials.gov registry entry for NCT07287332 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,561-participant average among 90 other Sepsis trials with a reported enrollment target (95% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Sepsis appearing as the primary indexed condition, and to 2 interventions - of which Usual Care is the first listed.

NCT07287332 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT07287332 about?

NCT07287332 is a clinical study titled "BLOOM: Pragmatic Feasibility Trial". The goal of this study is to compare two different ways of dosing cefepime, an antibiotic for very sick patients - the usual approach to dosing or a new dosing method. The new dosing method uses only doses that are available in normal care, but choosing between the different doses is based on more i...

What is the current status of trial NCT07287332?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2026-01-15. Estimated completion is 2027-07.

What conditions does trial NCT07287332 study?

This clinical trial studies the following conditions: Sepsis, Infection.

What interventions are being tested in trial NCT07287332?

The interventions under investigation include: Usual Care (OTHER), Up-front individualized dosing algorithm (OTHER).

Who is sponsoring clinical trial NCT07287332?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07287332 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sepsis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.